Bio-Techne sinks as fiscal Q3 revenue misses on weaker academic demand
TECH•Bio-Techne shares fell after fiscal Q3 2026 results missed Wall Street revenue expectations, with sales down 2% year over year to $311.4 million. Management pointed to demand pressure tied to weaker U.S. academic funding plus a tough comparison from prior-year GMP fast‑track orders and shipment timing.
1. What happened
Bio-Techne (NASDAQ: TECH) is sliding after releasing fiscal third-quarter 2026 results that came in lighter than expected on the top line, triggering a negative re-pricing of near-term growth expectations. The company posted net sales of $311.4 million, down 2% year over year, which landed below consensus expectations cited by market reports and helped drive the selloff. (stocktitan.net)
